Live SMT enables discovery of RUVBL inhibitors

RuvB-like 1 (RUVBL1) and its paralogue RuvB-like 2 (RUVBL2) are evolutionarily conserved members of the ATPases associated with diverse cellular activities (AAA) superfamily. In a recent study, researchers from Eikon Therapeutics Inc. aimed to leverage the protein dynamics of RUVBL1/2 to facilitate the development of novel inhibitors, instead of using ADP-based biochemical assays, to explore the therapeutic potential of this target.